DE69514342T2 - Modifizierte polypeptide mit erhoehter biologischer aktivitaet - Google Patents

Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Info

Publication number
DE69514342T2
DE69514342T2 DE69514342T DE69514342T DE69514342T2 DE 69514342 T2 DE69514342 T2 DE 69514342T2 DE 69514342 T DE69514342 T DE 69514342T DE 69514342 T DE69514342 T DE 69514342T DE 69514342 T2 DE69514342 T2 DE 69514342T2
Authority
DE
Germany
Prior art keywords
modified polypeptides
biological activity
increased biological
increased
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69514342T
Other languages
English (en)
Other versions
DE69514342D1 (de
Inventor
J Sytokowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Publication of DE69514342D1 publication Critical patent/DE69514342D1/de
Application granted granted Critical
Publication of DE69514342T2 publication Critical patent/DE69514342T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69514342T 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet Expired - Fee Related DE69514342T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/216,259 US5580853A (en) 1994-03-22 1994-03-22 Modified polypeptides with increased biological activity
PCT/US1995/003242 WO1995025746A1 (en) 1994-03-22 1995-03-15 Modified polypeptides with increased biological activity

Publications (2)

Publication Number Publication Date
DE69514342D1 DE69514342D1 (de) 2000-02-10
DE69514342T2 true DE69514342T2 (de) 2000-11-30

Family

ID=22806382

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69514342T Expired - Fee Related DE69514342T2 (de) 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Country Status (9)

Country Link
US (1) US5580853A (de)
EP (1) EP0751959B1 (de)
AT (1) ATE188486T1 (de)
DE (1) DE69514342T2 (de)
DK (1) DK0751959T3 (de)
ES (1) ES2143620T3 (de)
GR (1) GR3033146T3 (de)
PT (1) PT751959E (de)
WO (1) WO1995025746A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
AU733212B2 (en) 1996-03-28 2001-05-10 Board Of Trustees Of The University Of Illinois, The Material and methods for making improved liposome compositions
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
CA2499211A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Modified peptides yy and conjugates thereof
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU754770B2 (en) * 1999-05-17 2002-11-21 Conjuchem Biotechnologies Inc. Long lasting insulinotropic peptides
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
ATE428790T1 (de) 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression
AU2002233082B2 (en) * 2001-02-02 2005-11-10 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
WO2002066511A2 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1613274B1 (de) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Humane il-18 substitutionsmutanten und deren konjugate
EP1625156B1 (de) * 2003-05-12 2012-09-19 Affymax, Inc. An den erythropoietinrezeptor bindenden peptiden
JP4266028B2 (ja) * 2003-05-12 2009-05-20 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
EP2204193A3 (de) * 2003-05-12 2010-08-18 Affymax, Inc. Spacer-Bestandteile für Poly(ethylenglykol)-modifizierte Verbindungen auf Peptidbasis
WO2004101600A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
EP2230257A1 (de) 2004-04-23 2010-09-22 ConjuChem Biotechnologies Inc. Verfahren zur Reinigung von Albuminkonjugaten
KR20070108140A (ko) * 2004-11-11 2007-11-08 아피맥스, 인크. 에리트로포이에틴 수용체에 결합하는 신규한 펩타이드
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006063055A2 (en) * 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
CN101124243A (zh) * 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
WO2006086733A2 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
ES2390826T3 (es) * 2005-08-24 2012-11-16 Immunogen Inc Procedimiento para preparar conjugados de fármaco purificados
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
HUE043645T2 (hu) 2009-06-03 2019-08-28 Immunogen Inc Konjugációs módszerek
PL2691155T3 (pl) 2011-03-29 2019-06-28 Immunogen, Inc. Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem
US9243049B2 (en) 2011-08-09 2016-01-26 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
EP0751959A1 (de) 1997-01-08
US5580853A (en) 1996-12-03
ATE188486T1 (de) 2000-01-15
DK0751959T3 (da) 2000-06-26
DE69514342D1 (de) 2000-02-10
ES2143620T3 (es) 2000-05-16
GR3033146T3 (en) 2000-08-31
EP0751959B1 (de) 2000-01-05
WO1995025746A1 (en) 1995-09-28
PT751959E (pt) 2000-06-30

Similar Documents

Publication Publication Date Title
DE69514342T2 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
IT8812558A0 (it) Poltrona per abbronzatura
DK14890A (da) Peptider med t-hjaelpercelleaktivitet
ES8506087A1 (es) Procedimiento para preparar proteina de uroquinasa humana bioactiva
DE3882593T2 (de) Polypeptid und dessen Herstellung.
DK267885A (da) Maebel, saasom sidde- eller liggemaebel
IT8867463A0 (it) Sedia con sedile oscillante
ES2177625T3 (es) Citoquina cc-1 humana circulante.
DE58902290D1 (de) Sauerstoffabsorptionsmittel und verwendung desselben.
DK50987A (da) Polypeptid med plasminogenaktivatorvirkning
DE3886517T2 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DE3853743D1 (de) Rekombinanter menschlicher ADF.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
KR890015933U (ko) 회전의자
DK527287A (da) Polypeptid med interleukin-2-aktiviteter
DE68924022T2 (de) Protein mit hemmender Aktivität gegenüber menschlichem Plasmin.
DE3782199D1 (de) Biologisch aktive peptide tan-866.
NO912072D0 (no) Rekombinante proteiner med adipsin- og komplement-d-aktiviteter.
DE69019581D1 (de) Polypeptid und dieses enthaltende antibaktierelle Präparate.
IT8619477A0 (it) Sostanza ad attivita'nootropa e psicostimolante.
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.
KR850007051U (ko) 요동식 침대의자
KR880014653U (ko) 회전 의자
ATE92106T1 (de) Polypeptid und dessen herstellung.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., BOSTON

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee